Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety (Q35881304)

10 August 2017

1 reference

title

Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety (English)

1 reference

inflammatory bowel diseases

10 August 2017

main subject

0 references

1 reference

0 references

1 reference

Marla C Dubinsky

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Clinical Gastroenterology and Hepatology

10 August 2017

published in

1 reference

10 August 2017

volume

2

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

731-743

1 reference

Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

The clinical pharmacology of 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Polymorphism of the thiopurine S-methyltransferase gene in African-Americans

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Thiopurine S-methyltransferase activity in a Chinese population

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6‐mercaptopurine and azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Controlled trial of azathioprine in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Controlled trial of azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

A controlled double blind study of azathioprine in the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Frequency of glucocorticoid resistance and dependency in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

A controlled trial of azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Predictive Factors of Response of Perianal Crohn's Disease to Azathioprine or 6-Mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Drug interaction between infliximab and azathioprine in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Controlled trial of azathioprine in chronic ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Inflammatory bowel disease is not associated with an increased risk of lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Cancer risk in patients with inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Azathioprine, mercaptopurine and birth outcome: a population-based cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

6-mercaptopurine metabolite levels in children with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Utility of Measuring 6-Methylmercaptopurine and 6-Thioguanine Nucleotide Levels in Managing Inflammatory Bowel Disease Patients Treated With 6-Mercaptopurine in a Clinical Practice Setting

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900344-1

7 January 2021

10.1016/S1542-3565(04)00344-1

Identifiers

DOI

1 reference

10 August 2017

1 reference